China Journal of Leprosy and Skin Diseases ›› 2022, Vol. 38 ›› Issue (7): 466-468.doi: 10.12144/zgmfskin202207466

• Case Reports • Previous Articles     Next Articles

Treatment of Sézary syndrome with brentuximab vedotin: a case report

ZHANG Ke1, SHAO Shihong2, XUE Hongwei3, CHEN Guanzhi1, XIAO Shuxin3   

  1. 1 Department of Dermatology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China;2 Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China; 3 Department of Lymphology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China
  • Online:2022-07-15 Published:2022-05-17

Abstract: A 41-year-old male presented with diffuse erythema with severe pruritus for 1 year and multiple lymph node enlargement for 3 months. PET/CT image was consistent with lymphoma, pathology of lymph node showed non-Hodgkin T cell lymphoma, with irregular, twisted, and cerebriform nuclei. Skin pathology showed non-Hodgkin T cell lymphoma presenting with mycosis fungoides. Sézary syndrome was diagnosed according the above examinations and T cell gene rearrangement in peripheral blood. The effect of chemotherapy and other first-line drugs was not good, then the treatment regimen containing brentuximab vedotin was given, with good effect of erythema subsided, pruritus disappeared, lymph nodes decreased.

Key words: Sézary syndrome, cutaneous T-cell lymphoma, brentuximab vedotin